Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee.

Details

Ressource 1Download: BIB_22BFE2C6FAC4.P001.pdf (123.82 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_22BFE2C6FAC4
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee.
Journal
Annals of Oncology
Author(s)
Psyrri A., Licitra L., Lacombe D., Schuuring E., Budach W., Ozsahin M., Knecht R., Vermorken J.B., Langendijk J.A.
ISSN
1569-8041[electronic], 0923-7534[linking]
Publication state
Published
Issued date
2010
Volume
21
Number
10
Pages
1952-1960
Language
english
Abstract
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths worldwide. These tumors are commonly diagnosed at advanced stages and mortality rates remain high. Even cured patients suffer the consequences of aggressive treatment that includes surgery, chemotherapy, and radiotherapy. In the past, in clinical trials, HNSCC was considered as a single disease entity. Advances in molecular biology with the development of genomic and proteomic approaches have demonstrated distinct prognostic HNSCC patient subsets beyond those defined by traditional clinical-pathological factors such as tumor subsite and stage [Cho W (ed). An Omics Perspective on Cancer Research. New York/Berlin: Springer 2010]. Validation of these biomarkers in large prospective clinical trials is required before their clinical implementation. To promote this research, the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Program will develop the following strategies-(i) biobanking: prospective tissue collection from uniformly treated patients in the setting of clinical trials; (ii) a group of physicians, physician-scientists, and EORTC Headquarters staff devoted to patient-oriented head and neck cancer research; (iii) a collaboration between the basic scientists of the Translational Research Division interested in head and neck cancer research and the physicians of the Head and Neck Cancer Group; and (iv) funding through the EORTC Grant Program and the Network Core Institutions Consortium. In the present report, we summarize our strategic plans to promote head and neck cancer research within the EORTC framework.
Keywords
EGFR, head and neck cancer, HPV, translational research, squamous-cell carcinoma, epidermal-growth-factor, human-papillomavirus infection, laryngeal carcinoma, plus cetuximab, molecular classification, randomized-trial, gene-expression, receptor, radiotherapy
Pubmed
Web of science
Open Access
Yes
Create date
21/10/2010 7:58
Last modification date
20/08/2019 13:00
Usage data